Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Olivier Bylicki"'
Autor:
Gilles Robinet, Christos Chouaid, Radj Gervais, Roland Schott, Florian Guisier, Chantal Decroisette, Jean-Bernard Auliac, Olivier Bylicki, Charles Ricordel, Laurent Greillier, Maurice Pérol, Benjamin Besse, Renaud Descourt
Publikováno v:
Future Oncology
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer withoutLay abstract Non-small-cell lung cancer (NSCLC) is the most frequent type of lung cancer. Most NSCLC patients are diagnosed wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d4948a536b358f6ce91b90b9bc53c5
https://inria.hal.science/hal-03526346
https://inria.hal.science/hal-03526346
Autor:
R. Lamy, Christos Chouaid, Hélène Doubre, Pierre Fournel, Olivier Bylicki, Isabelle Monnet, Radj Gervais, H. Janicot, Jean-Bernard Auliac, Florian Guisier, Maurice Pérol
Publikováno v:
Medicine
Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against epidermal growth-factor receptor (EG
Autor:
Nicolas Paleiron, Jacques Margery, Christos Chouaid, Jean-Baptiste Assié, Hélène Barazzutti, Olivier Bylicki
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 33(2)
Treatment of advanced-stage or metastatic non-small-cell lung cancers (NSCLCs) without EGFR mutations or ALK rearrangements, which can now be treated with molecularly targeted therapies, had been based on cytotoxic chemotherapy for a long time. Immun